Acute rheumatic fever and rheumatic heart disease: what's new?

Rheumatic heart disease (RHD) is a preventable heart disease that remains endemic in developing countries. More than 30 million people in the world suffer from RHD, of which approximately 300,000 die every year, despite the fact that this disease is preventable and treatable. After a period of relative neglect of rheumatic heart diseases due to a decrease in the incidence in developed countries, interest in this problem has increased again over the past decade, due, apparent­ly, to an underestimation of its true prevalence due to the subclinical course of carditis. Research over the past two decades has demonstrated the advantage of diagnosing RHD with echocardiographic screening based on World Heart Federation echocardiographic criteria, which is 10 times greater than the clinical auscultatory picture only and it allows
early detection of it in patients, while prevention is to be more likely to be effective. Although understanding of the pathogenesis of the disease has advanced in recent years, key issues remain unresolved. Preventing or providing early treatment for streptococcal infections is the most important step in reducing the burden of this disease. The manage­ment of women with rheumatic heart disease before, during and after pregnancy remains a serious task requiring the efforts of a multidisciplinary team. In 2015, a civil society movement was launched aimed at raising awareness and supporting countries seeking to solve the RHD problem. In May 2018, the World Health Organization adopted a resolu­tion aimed at intensifying global and national efforts to prevent and combat acute rheumatic fever/RHD. Ultimately, a combination of treatment options, research and advocacy based on existing knowledge and science provides the best opportunity to cope with the burden of rheumatic heart disease. The article summarizes the latest achievements in the science of RHD and presents priorities for current actions and future research.

1. Watkins D.A., Johnson C.O., Colquhoun S.M. et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med 2017;377(8):713-22. DOI: 10.1056/NEJMoa1603693

2. Meira Z.M., Goulart E.M., Colosimo E.A., Mota C.C. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. Heart 2005;91(8):1019-22. DOI: 10.1136/hrt.2004.042762

3. Longo-Mbenza B., Bayekula M., Ngiyulu R. et al. Survey of rheu¬matic heart disease in school children of Kinshasa town. Int J Car¬diol 1998;63(3):287-94. DOI: 10.1016/s0167-5273(97)00311-2

4. Watkins D.A., Beaton A.Z., Carapetis J.R. et al. Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel. J Am Coll Cardiol 2018;72(12):1397-416. DOI: 10.1016/j.jacc.2018.06.063

5. Doukky R., Abusin S.A., Bayissa Y.A. et al. Rheumatic heart disease in modern urban America: a cohort study of immigrant and indigenous patients in Chicago. Int J Cardiol 2014;175(1):178-80. DOI: 10.1016/j.ijcard.2014.04.207

6. Rothenbuhler M., O'Sullivan C.J., Stortecky S. et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. Lancet Glob Health 2014;2(12):e717-26. DOI: 10.1016/S2214-109X(14)70310-9

7. Carapetis J.R., Zuhlke L.J. Global research priorities in rheumatic fever and rheumatic heart disease. Ann Pediatr Cardiol 2011;4(1):4-12. DOI: 10.4103/0974-2069.79616

8. Gordis L. The virtual disappearance of rheumatic fever in the United States: lessons in the rise and fall of disease. T. Duckett Jones memorial lecture. Circulation 1985;72(6):1155-62. DOI: 10.1161/01.cir.72.6.1155

9. Massell B.F., Chute C.G., Walker A.M., Kurland G.S. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med 1988;318(5):280-6. DOI: 10.1056/NEJM198802043180504

10. EXPERT committee on rheumatic diseases; first report. World Health Organ Tech Rep Ser 1954;78:1-25. PMID: 13157434

11. Bach J.F., Chalons S., Forier E. et al. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet 1996;347(9002):644-8. DOI: 10.1016/s0140-6736(96)91202-7

12. Nordet P., Lopez R., Duenas A., Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986-1996-2002). Cardiovasc J Afr 2008;19(3): 135-40. PMID: 18568172

13. Gunther G., Asmera J., Parry E. Death from rheumatic heart disease in rural Ethiopia. Lancet 2006;367(9508):391. DOI: 10.1016/S0140-6736(06)68128-2

14. Colquhoun S.M., Condon J.R., Steer A.C. et al. Disparity in mortality from rheumatic heart disease in indigenous Australians. J Am Heart Assoc 2015;4(7):e001282. DOI: 10.1161/JAHA.114.001282

15. Parks T., Kado J., Miller A.E. et al. Rheumatic heart disease- attributable mortality at ages 5-69 years in Fiji: a five-year, national, population-based record-linkage cohort study. PloS Negl Trop Dis 2015;9(9):e0004033. DOI: 10.1371/journal.pntd.0004033

16. Maurice J. Rheumatic heart disease back in the limelight. Lancet 2013;382(9898):1085-6. DOI: 10.1016/s0140-6736(13)61972-8

17. Marijon E., Ou P., Celermajer D.S. et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007;357(5):470-6. DOI: 10.1056/NEJMoa065085

18. Global action plan for the prevention and control of noncom-municable diseases 2013-2020. Geneva: World Health Organization, 2013. Available at: https://apps.who.int>iris/handle/10665/94384

19. Remenyi B., Carapetis J., Wyber R. et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol 2013;5(10):284-92. DOI: 10.1038/nrcardio.2013.34

20. Francis J.R., Gargan C., Remenyi B. et al. A cluster of acute rheumatic fever cases among Aboriginal Australians in a remote community with high baseline incidence. Aust NZJ Public Health 2019;43(3):288-93. DOI: 10.1111/1753-6405.12893

21. Pastore S., De Cunto A., Benettoni A. et al. The resurgence of rheumatic fever in a developed country area: the role of echo-cardiography. Rheumatology (Oxford) 2011;50(2):396-400. DOI: 10.1093/rheumatology/keq290

22. Veasy L.G., Wiedmeier S.E., Orsmond G.S. et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987;316(4):421-7. DOI: 10.1056/NEJM198702193160801

23. Kumar R.K., Tandon R. Rheumatic fever & rheumatic heart disease: the last 50 years. Indian J Med Res 2013;137(4):643-58. PMID: 23703332

24. Kuzmina N.N., Medyntseva L.G., Belov B.S. Rheumatic fever: Semicentennial experience in studying the problem. Razmy'shleniya revmatologa. Nauchno-prakticheskaya revmatologiya = Reflections of a rheumatologist. Rheumatology Science and Practice 2017;55(2):125-37 (In Russ.). DOI: 10.14412/1995-4484-2017-125-137

25. Morbidity of the population of Russia in 2014. Statistical materials. Moscow, 2015. 

26. Aksenova A.V., Abeldyaev D.V., Glushkova E.V. Current epidemiological aspects of streptococcal and post-streptococcal diseases in the Russian Federation. Klinitsist = The Clinician 2020;14(1-2):14-23. (In Russ.). DOI: 10.17650/1818-8338-2020¬14-1-2-14-23

27. Gewitz M.H., Baltimore R.S., Tani L.Y. et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015;131(20):1806- 18. DOI: 10.1161/CIR.0000000000000205

28. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation, Geneva, 29 October - 1 November 2001. Geneva: World Health Organization, 2004. Available at: https://apps.who.int/iris/handle/10665/42898

29. Tubridy-Clark M., Carapetis J.R. Subclinical carditis in rheumatic fever: a systematic review. Int J Cardiol 2007;119(1):54-8. DOI: 10.1016/j.ijcard.2006.07.046.

30. Zuhlke L., Engel M.E., Karthikeyan G. et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015;36(18):1115-22a. DOI: 10.1093/eurheartj/ehu449

31. Wilson N.J., Voss L., Morreau J. et al. New Zealand guidelines for the diagnosis of acute rheumatic fever: small increase in the inci-dence of definite cases compared to the America Heart Association Jones criteria. N Z Med J 2013;126(1379):50-9. PMID: 24045352

32. Remenyi B., Wilson N., Steer A. et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease: an evidence-based guideline. Nat Rev Cardiol 2012;9(5):297-309. DOI: 10.1038/nrcardio.2012.7

33. Watkins D., Beaton A. Carapetis J.R. et al. Rheumatic Heart Disease Worldwide: JACC Scientific Expert Panel. J Am Coll Cardiol 2018;72(12):1397-416. DOI: 10.1016/j.jacc.2018.06.063

34. Abernethy M., Bass N., Sharpe N. et al. Doppler echocardiography and the early diagnosis of carditis in acute rheumatic fever. Aust N Z J Med 1994;24(5):530-5. DOI: 10.1111/j.1445-5994.1994.tb01753.x

35. Minich L.L., Tani L.Y., Pagotto L.T. et al. Doppler echocardio¬graphy distinguishes between physiologic and pathologic “silent” mitral regurgitation in patients with rheumatic fever. Clin Cardiol 1997;20(11):924-6. DOI: 10.1002/clc.4960201105

36. World Health Organization. WHA71.14: Rheumatic Fever and Rheumatic Heart Disease. 2018. Available at: https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_R14-en.pdf

37. Watkins D.A., Sebitloane M., Engel M.E., Mayosi B.M. The burden of antenatal heart disease in South Africa: a systematic review. BMC Cardiovasc Disord 2012;12:23. DOI: 10.1186/1471-2261-12-23

38. Anthony J., Osman A., Sani M.U. Valvular heart disease in pre¬gnancy. Cardiovasc J Afr 2016;27(2):111-8. DOI: 10.5830/CVJA-2016-052

39. van Hagen I.M., Thorne S.A., Taha N. et al. Pregnancy outcomes in women with rheumatic mitral valve disease: results from the Registry of Pregnancy and Cardiac Disease. Circulation 2018;137(8):806-16. DOI: 10.1161/CIRCULATIONAHA.117.032561

40. Rezk M., Elkilani O., Shaheen A. et al. Maternal hemodynamic changes and predictors of poor obstetric outcome in women with rheumatic heart disease: a five-year observational study. J Matern Fetal Neonatal Med 2018:131(12):1542-7. DOI: 10.1080/14767058.2017.1319932

41. Diao M., Kane A., Ndiaye M.B. et al. Pregnancy in women with heart disease in sub-Saharan Africa. Arch Cardiovasc Dis 2011;104(6-7):370-4. DOI: 10.1016/j.acvd.2011.04.001

42. Otto H., Saether S.G., Banteyrga L. et al. High prevalence of sub- clinical rheumatic heart disease in pregnant women in a developing country: an echocardiographic study. Echocardiography 2011;28(10):1049-53. DOI: 10.1111/j.1540-8175.2011.01520.x

43. D'Souza R., Ostro J., Shah P.S. et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J 2017;389190:1509-16. DOI: 10.1093/eurheartj/ehx032

44. Xu Z., Fan J., Luo X. et al. Anticoagulation regimens during pregnancy in patients with mechanical heart valves: a systematic review and meta-analysis. Can J Cardiol 2016;32(10):1248.e1-9. DOI: 10.1016/j.cjca.2015.11.005

45. French K.A., Poppas A. Rheumatic heart disease in pregnancy: global challenges and clear opportunities. Circulation 2018;137(8): 817-9. DOI: 10.1161/CIRCULATIONAHA.118.033465